<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Twenty-three patients with primary <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) or secondary <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo>/<z:hpo ids='HP_0011009'>acute</z:hpo> nonlymphocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/ANLL) were treated with allogeneic or syngeneic bone marrow transplantation (BMT) </plain></SENT>
<SENT sid="1" pm="."><plain>Only one patient was in a chemotherapy-induced hematologic remission </plain></SENT>
<SENT sid="2" pm="."><plain><z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">Graft-versus-host disease</z:e> prophylaxis included <z:chebi fb="0" ids="44185">methotrexate</z:chebi>, <z:chebi fb="0" ids="44185">methotrexate</z:chebi> plus <z:chebi fb="0" ids="4031">cyclosporine</z:chebi>, <z:chebi fb="0" ids="4031">cyclosporine</z:chebi>, or T-cell <z:mpath ids='MPATH_63'>depletion</z:mpath> using one of two anti-CD5 monoclonal antibodies </plain></SENT>
<SENT sid="3" pm="."><plain>For patients with primary <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, the median age was 19 years (range, 11 to 41 years) and the actuarial disease-free survival was 56% +/- 21% (median follow-up, 2 years; range, 0.8 to 5 years) </plain></SENT>
<SENT sid="4" pm="."><plain>There were three graft failures (two with autologous recovery) and two early <z:hpo ids='HP_0011420'>deaths</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>Outcome appeared to be related to French-American-British (FAB) classification </plain></SENT>
<SENT sid="6" pm="."><plain>For patients with <z:e sem="disease" ids="C0280745" disease_type="Neoplastic Process" abbrv="">secondary MDS</z:e>/ANLL, the median age was 28 years (range, 3 to 16 years) and the actuarial disease-free survival was 27% +/- 13% (median follow-up, 5 years; range, 2.5 to 8.5 years) </plain></SENT>
<SENT sid="7" pm="."><plain>There were no graft failures, two relapses, and four early <z:hpo ids='HP_0011420'>deaths</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>The presence of marrow <z:mp ids='MP_0003045'>fibrosis</z:mp> per se did not predict for graft failure (P = .21); however, the use of T-cell depleted marrow in patients with marrow <z:mp ids='MP_0003045'>fibrosis</z:mp> resulted in graft failure in three of five individuals </plain></SENT>
<SENT sid="9" pm="."><plain>Our results suggest that in patients with primary <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> or <z:e sem="disease" ids="C0280745" disease_type="Neoplastic Process" abbrv="">secondary MDS</z:e>/ANLL, BMT should be considered early in the course of the disease, and that attempts at inducing a remission prior to BMT appeared to be unnecessary </plain></SENT>
<SENT sid="10" pm="."><plain>In <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients with marrow <z:mp ids='MP_0003045'>fibrosis</z:mp>, T-cell <z:mpath ids='MPATH_63'>depletion</z:mpath> should be avoided </plain></SENT>
</text></document>